Baidu
map

药品信息速递

订阅

MedSci主页 / 所有栏目 / 药品信息速递

诺华的Kymriah在血癌中表现出持久应答

2017-12-11 MedSci MedSci原创

Kymriah血癌
关注

在第59届美国血液学会（ASH）年会上提出的关于诺华CAR-T疗法Kymriah的试验数据的新分析显示，该药在6个月时对于难以治疗的血癌形式的成人持续完全应答。CAR-T提供了一种新的治疗方法，因为它是专门为每个病人制造的。在这个过程中，从患者的血液中提取T细胞，并在实验室中重新编程以创建基因编码的T细胞来狩猎患者的癌细胞。由宾夕法尼亚大学(Penn)的研究人员领导的"朱丽叶试验"(Juliet

在第59届美国血液学会（ASH）年会上提出的关于诺华CAR-T疗法Kymriah的试验数据的新分析显示，该药在6个月时对于难以治疗的血癌形式的成人持续完全应答。CAR-T提供了一种新的治疗方法，因为它是专门为每个病人制造的。在这个过程中，从患者的血液中提取T细胞，并在实验室中重新编程以创建基因编码的T细胞来狩猎患者的癌细胞。由宾夕法尼亚大学(Penn)的研究人员领导的"朱丽叶试验"(Juliet trial)的数据显示，在接受Kymriah(tisagenlecleucel)的患者中，患者的总体反应率(ORR)为53%，40%的患者获得完全反应(CR)，患者部分应答率(PR)为14%。6个月时，30％的患者完全缓解，74％的患者在应答后无复发，然而没有达到中位缓解时间。这项研究的主要研究人员Stephen J. Schuster说："在试验入选时，这些DLBCL患者已经经历了多轮化疗，许多患者干细胞移植失败，使得他们的选择不多，预后也很差。""使用tisagenlecleucel，我们已经能够显著提高他们实现和维持持续应答的机会，而无需干细胞移植，从而证明了这种治疗方法在治疗这种致命的

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2025293, encodeId=49452025293f9, content=<a href='/topic/show?id=e8b01060688' target=_blank style='color:#2F92EE;'>#Kymriah#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10606, encryptionId=e8b01060688, topicName=Kymriah)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Jul 26 09:34:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282712, encodeId=01cd1282e123f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 13 11:34:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589578, encodeId=320115895e8b5, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Wed Dec 13 11:34:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2018-07-26 grace5700

    #Kymriah#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2025293, encodeId=49452025293f9, content=<a href='/topic/show?id=e8b01060688' target=_blank style='color:#2F92EE;'>#Kymriah#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10606, encryptionId=e8b01060688, topicName=Kymriah)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Jul 26 09:34:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282712, encodeId=01cd1282e123f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 13 11:34:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589578, encodeId=320115895e8b5, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Wed Dec 13 11:34:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 nian.wang1982

    #诺华#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2025293, encodeId=49452025293f9, content=<a href='/topic/show?id=e8b01060688' target=_blank style='color:#2F92EE;'>#Kymriah#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10606, encryptionId=e8b01060688, topicName=Kymriah)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b05b180, createdName=grace5700, createdTime=Thu Jul 26 09:34:00 CST 2018, time=2018-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1282712, encodeId=01cd1282e123f, content=<a href='/topic/show?id=2df29190553' target=_blank style='color:#2F92EE;'>#诺华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91905, encryptionId=2df29190553, topicName=诺华)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f63175, createdName=nian.wang1982, createdTime=Wed Dec 13 11:34:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1589578, encodeId=320115895e8b5, content=<a href='/topic/show?id=8b378949642' target=_blank style='color:#2F92EE;'>#血癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89496, encryptionId=8b378949642, topicName=血癌)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8db117750430, createdName=liuhuangbo, createdTime=Wed Dec 13 11:34:00 CST 2017, time=2017-12-13, status=1, ipAttribution=)]
    2017-12-13 liuhuangbo

    #血癌#

    0

Baidu
map
Baidu
map
Baidu
map